A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly and Company · NCT07589608
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 400
- US sites recruiting
- 40
- Study start
- May 15, 2026
- Record last updated
- October 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Being studied: Macupatide; Eloralintide; Placebo
Conditions: Overweight; Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- See Master Protocol CWMM (NCT06143956) for inclusion criteria
Exclusion Criteria
In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):
- Have type 1 diabetes or type 2 diabetes
- Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
- Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
- Have a history of acute or chronic pancreatitis
- All concomitant medications should be at a stable dose for at least 3 months prior to screening
Recruiting US locations
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, AZ 85225
Site contact: Yessica Sachdeva
Headlands Research - Scottsdale
Scottsdale, AZ 85260
Site contact: Benjamin Clark
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, AZ 85712
Site contact: Anita Kohli
NorCal Medical Research, Inc
Greenbrae, CA 94904
Site contact: Linda Gaudiani
Velocity Clinical Research, Huntington Park
Huntington Park, CA 90255
Site contact: Stanley Hsia
Peninsula Research Associates
Rolling Hills Estates, CA 90274
Site contact: LeighAnn Schmidt
Diablo Clinical Research, Inc.
Walnut Creek, CA 94598
Site contact: Bonnie Kimmel
Stamford Therapeutics Consortium
Stamford, CT 06905
Site contact: David Radin
New Horizon Research Center
Miami, FL 33165
Site contact: Lazaro Nunez
Indago Research & Health Center, Inc
Miami Lakes, FL 33016
Site contact: Jose Cardona
Suncoast Clinical Research, Inc.
New Port Richey, FL 34652
Site contact: Cathy Barnes
Charter Research - Winter Park
Orlando, FL 32803
Site contact: Edgardo Rivera-Rivera
Charter Research - Lady Lake
The Villages, FL 32162
Site contact: Jeffrey Norton
Medical Research Partners
Ammon, ID 83406
Site contact: Joseph Moore
Great Lakes Clinical Trials - Ravenswood
Chicago, IL 60640
Site contact: Rupal Trivedi
Cotton O'Neil Diabetes & Endocrinology
Topeka, KS 66606
Site contact: susan brian
Monroe Biomedical Research - Louisville
Louisville, KY 40213
Site contact: Harold Bays
Knownwell
Needham, MA 02492
Site contact: Angela Fitch
Lucida Clinical Trials
New Bedford, MA 02740
Site contact: David Shih
Headlands Research - Detroit
Southfield, MI 48034
Site contact: Christopher Romero
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, MI 48098
Site contact: Neil Fraser
StudyMetrix Research
City of Saint Peters, MO 63303
Site contact: Timothy Smith
Clinvest Headlands Llc
Springfield, MO 65807
Site contact: Christina Capps
Las Vegas Medical Research
Las Vegas, NV 89128
Site contact: Cornell Calinescu
Dent Neurologic Institute
Amherst, NY 14226
Site contact: Laszlo Mechtler
Rochester Clinical Research, LLC
Rochester, NY 14609
Site contact: Patrick Connors
Medication Management
Greensboro, NC 27401
Site contact: James Franklin
Monroe Biomedical Research
Monroe, NC 28112
Site contact: Awawu Igbinadolor
Lucas Research, Inc
Morehead City, NC 28557
Site contact: Kathryn Lucas
Lucas Research, Inc.
New Bern, NC 28562
Site contact: Joseph Maides
CTI Clinical Research Center
Cincinnati, OH 45212
Site contact: James Maynard
Tribe Clinical Research, LLC
Greenville, SC 29607
Site contact: Ronald Mayfield
Quality Medical Research
Nashville, TN 37211
Site contact: Saras Sharma
IMA Clinical Research Austin
Austin, TX 78745
Site contact: Nomita Kim
FutureSearch Trials of Dallas
Dallas, TX 75251
Site contact: Michael Downing
PlanIt Research, PLLC
Houston, TX 77079
Site contact: Amer Al-Karadsheh
Endeavor Clinical Trials
San Antonio, TX 78240
Site contact: Nitendra Agarwal
Texas Valley Clinical Research
Weslaco, TX 78596
Site contact: Eduardo Luna
Sovah Clinical Research-River District
Danville, VA 24541
Site contact: Stephan Jannach
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, WA 98801
Site contact: Kathryn Eren
Study contacts (from the official record)
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
- Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Similar studies in Arizona
All weight loss studies in Arizona →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Chandler, AZ + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Chandler, AZ + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Scottsdale, AZ + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Sun City, AZ + 19 other US sites
- Eligibility basics
- Ages 18–75